Ultragenyx to Participate at Investor Conferences in November
November 20 2023 - 4:30PM
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical
company focused on the development and commercialization of novel
therapies for serious rare and ultrarare genetic diseases, today
announced that management, will participating in two upcoming
investor conferences.
6th Annual Evercore
ISI HealthCONx (Miami, FL)
- Tuesday, November 28, 2023,
management will host 1x1 meetings.
Piper Sandler 35th
Annual Healthcare Conference (New York City,
NY)
- Wednesday, November 29, 2023, at
10:00am, Emil Kakkis, M.D., Ph.D., CEO and President, will
participate in a fireside chat and host 1x1 meetings.
The live and archived webcast of the fireside chat will be
accessible from the company’s website at
https://ir.ultragenyx.com/events-presentations.
About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing
novel products to patients for the treatment of serious rare and
ultrarare genetic diseases. The company has built a diverse
portfolio of approved therapies and product candidates aimed at
addressing diseases with high unmet medical need and clear biology
for treatment, for which there are typically no approved therapies
treating the underlying disease.
The company is led by a management team experienced in the
development and commercialization of rare disease therapeutics.
Ultragenyx’s strategy is predicated upon time- and cost-efficient
drug development, with the goal of delivering safe and effective
therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's
website at: www.ultragenyx.com.
Contacts – Ultragenyx Pharmaceutical,
Inc.Investorsir@ultragenyx.com
Mediamedia@ultragenyx.com
Ultragenyx Pharmaceutical (NASDAQ:RARE)
Historical Stock Chart
From May 2024 to Jun 2024
Ultragenyx Pharmaceutical (NASDAQ:RARE)
Historical Stock Chart
From Jun 2023 to Jun 2024